Sun Pharma and Philogen partner to market skin cancer drug

Sun Pharmaceutical Industries has recently entered into a licensing agreement with Philogen SpA to commercialize an under-development skin cancer drug in Europe, Australia, and New Zealand. The collaboration aims to bring Philogen's specialty product, Nidlegy, to market. Nidlegy is an anti-cancer biopharmaceutical currently undergoing Phase III clinical trials, specifically for the treatment of melanoma and non-melanoma skin cancers.

As per the agreement, Sun Pharma, headquartered in Mumbai, will have exclusive rights to commercialize Nidlegy. Philogen, a Swiss-Italian firm, will complete pivotal clinical trials in Europe, seek marketing authorization from regulatory authorities, and handle the manufacturing of commercial supplies. In terms of post-commercialization economics, both companies will share the profits in an approximately 50:50 ratio.

While specific financial details were not disclosed, Philogen will retain intellectual property rights for Nidlegy in territories and indications outside of skin cancers. Sun Pharma's Business Head for Western Europe and ANZ, Hellen De Kloet, expressed that this collaboration aligns with their objective of delivering innovative products to patients. By adding Nidlegy to their existing Odomzo franchise, Sun Pharma aims to offer comprehensive solutions for a wide range of skin cancers at different disease stages.